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Edited by Sandro SonninoAbstract Previous work has identiﬁed sphingosine kinase-1
(SK1) as a substrate for the cysteine protease cathepsin B
in vitro. In this study, the mechanism of SK1 cleavage by cathep-
sin B was investigated. We identiﬁed two initial cleavage sites for
the protease, the ﬁrst at histidine 122 and the second at arginine
199. Mutation analysis showed that replacement of histidine 122
with a tyrosine maintained the activity of SK1 while signiﬁcantly
reducing cleavage by cathepsin B at the initial cleavage site. The
eﬃcacy of cleavage of SK1 at arginine 199, however, was not af-
fected. These studies demonstrate that SK1 is cleaved by cathep-
sin B in a sequential manner after basic amino acids, and that the
initial cleavages at the two identiﬁed sites occur independently of
each other.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cathepsins constitute a family of proteases comprised of
aspartate proteases, such as cathepsins D and E, serine prote-
ases, such as cathepsins A and G, and cysteine proteases, such
as cathepsins B, C, H, K, L, S, and T [1]. Most cathepsin en-
zymes are endopeptidases, with a few, such as cathepsin B, that
can also act as carboxypeptidases [2,3]. Cathepsins B, D, and L
are the most abundant lysosomal proteases, having concentra-
tions as high as 1 mM [4]. They are ubiquitous enzymes whose
functions have been proposed to extend beyond the conﬁnes
of the lysosome. In fact, administration of cathepsin B and
cathepsin D inhibitors in rats did not result in endogenous pro-
tein accumulation in the lysosomes or impaired degradation
of exogenous protein [5], suggesting that the function of these
proteases in intralysosomal protein degradation is not essen-
tial, and that their activities may be important when they are
localized extralysosomally under physiological or pathological
conditions.
Several studies have proposed crucial extralysosomal func-
tions for cathepsin B. In addition to being localized in the lyso-*Corresponding author. Address: Department of Medicine, Medical
University of South Carolina, 114 Doughty Street, P.O. Box 250779,
Charleston, SC 29425, USA. Fax: +1 843 876 5172.
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cathepsin B) can be found on the surface or in the periplasmic
space of tumor cells [6–11], where it can promote invasion. In
the mitochondria [12], cathepsin B can mediate nuclear frag-
mentation. Cathepsin B has also been reported in other cellular
compartments [13]. The role of cathepsin B in apoptosis has re-
cently grown with the emerging evidence implicating the lyso-
some as a critical mediator of programmed cell death [14].
Under conditions where lysosomes become disrupted, cathep-
sin B is released into the cytosol where it mediates events such
as Bid cleavage [15,16] and cytochrome c release [17]. There-
fore, the localization of cathepsin B is an important determi-
nant of the eﬀects it produces.
Sphingosine kinase-1 (SK1) is a key enzyme in sphingolipid
metabolism that regulates the levels of the bioactive lipids cer-
amide, sphingosine, and sphingosine-1-phosphate (S1P). Over-
expression of SK1 enhances DNA synthesis, increases growth,
and inhibits apoptosis in response to several death-inducing
agents, including tumor necrosis factor (TNF), ceramide,
and genotoxic stress [18,19]. Activation of SK1 by agonist
stimulation or overexpression has been shown to attenuate
caspase activation and the mitochondrial pathway of cell death
[18,19]. The regulation of SK1 by proteases, however, has not
been investigated.
Recently, we have shown that cathepsin B and lysosomes
colocalize with SK1 in MCF-7 breast cancer cells [20]. More
importantly, tumor necrosis factor induced the disruption of
the lysosome, release of active cathepsin B into the cytosol,
and loss of SK1, an event inhibited by knocking down cathep-
sin B protein. Moreover, SK1 appeared to be a substrate for
cathepsin B in vitro [20].
In this study, we extend these observations to deﬁne the mul-
tiple cleavage sites for cathepsin B in SK1. Two initial cleavage
sites were identiﬁed, with one site appearing before the other.
Moreover, mutation in the initial site signiﬁcantly attenuated
cleavage by cathepsin B at that site while maintaining SK1
activity.2. Materials and methods
2.1. Chemicals and reagents
Recombinant human liver cathepsin B was from Calbiochem. The
rabbit polyclonal anti-SK1 antibody has been described previously
[21]. Recombinant SK1 was a kind gift from Dr. Wonhwa Cho (Uni-
versity of Illinois at Chicago). The C-terminus directed SK1 antibody
preparation has been described previously [21].blished by Elsevier B.V. All rights reserved.
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MCF-7 cells were cultured in RPMI 1640 supplemented with 10%
FBS, 100 U/ml penicillin, and 100 lg/ml streptomycin. Hela and
A549 cells were grown in DMEM supplemented with 10% FBS,
100 U/ml penicillin, and 100 lg/ml streptomycin.
2.3. Site-directed mutagenesis
SK1 point mutants were generated using the QuikChange Site-direc-
ted Mutagenesis Kit (Stratagene). Primers used were N121E (Fwd:
50-GCTGGCAGC TTC CTTGGAGCA TTA TGC TGGCTA TGA-
3 0, Rev: 5 0-TCA TAG CCA GCA TAA TGC TCC AAG GAA GCT
GCC AGC-3), H121E (Fwd: 5 0- GGC AGC TTC CTT GAA CGA
GTA TGC TGG CTA TGA GCA-30, Rev: 5 0- TGC TCA TAG
CCA GCA TAC TCG TTC AAG GAA GCT GCC-3 0), H122A
(Fwd: GGC AGC TTC CTT GAA CGC ATA TGC TGG CTA
TGA GCA GG-3 0, Rev: 5 0-CCT GCT CAT AGC CAG CAT ATG
CGT TCA AGG AAG CTG CC-3 0), Y123A (Fwd: 5 0-CAG CTT
CCT TGA ACC ATG CAG CTG GCT ATG AGC AGG TC-30,
Rev: 5 0-GAC CTG CTC ATA GCC AGC TGC ATG GTT CAA
GGA AGC TG-3 0), H122Y (Fwd: 5 0-GCA GCT TCC TTG AAC
TAT TAT GCT GGC TAT GAG C-3 0, Rev: 5 0-GCT CAT AGC
CAG CAT AAT AGT TCA AGG AAG CTG C-3 0). Mutants were
conﬁrmed by DNA sequencing.2.4. Transient transfection
MCF-7 or Hela cells were seeded in 10 cm dishes and transfected
with pcDNA-DEST40-SK1 wildtype or mutant using the Eﬀectene
transfection reagent (Qiagen). For MCF-7 cells, 2.0 lg DNA, 500 ll
EC buﬀer, 16 ll Enhancer, and 20 ll Eﬀectene were used. For Hela
cells, 1.0 lg DNA, 500 ll EC buﬀer, 8.0 ll Enhancer, and 10 ll Eﬀec-
tene were used. The cells were analyzed 24–30 h after transfection.
A549 cells in 60 mm dishes were transfected with the Eﬀectene trans-
fection reagent; 2.0 lg DNA, 150 ll EC Buﬀer, 16 ll Enhancer, and
20 ll Eﬀectene were used. Sixteen hours after transfection, the cells
were washed with PBS, and fresh growth media was added. Transfec-
tants were analyzed 24 h later.
2.5. In vitro cleavage assays of SK1 by cathepsin B
Transfected cells were harvested by scraping in PBS, and lysed on ice
for 30 min in Buﬀer L (25 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM
EGTA, 0.5% Triton X-100, 5 mM DTT). The lysate was homogenized
with a 21 G1 needle and centrifuged at 18000 · g for 30 min. For the
cathepsin B assay, 1.0 ll of recombinant SK1 (2 lg/ul) or 10–15 lg of
the supernatant proteins were diluted to 4.0 ll in Buﬀer L and then
added to 5 ll of 3· cathepsin B reaction buﬀer (150 mM sodium ace-
tate pH 6.0, 12 mM EDTA, 24 mM DTT) and 5.0 ll of recombinant
cathepsin B to achieve the ﬁnal concentrations required for the assay.
Whenever required, cathepsin B was diluted in 50 mM sodium acetate
pH 5.0, 1 mM EDTA prior to its use in the assay. The ﬁnal volume was
brought to 15 ll with ddH20. The cleavage assays were performed by
incubation at 37 C for the times indicated in the text. Following incu-
bation, 15 ll of 2· SDS-Laemmli sample buﬀer was added to the sam-
ples; they were boiled, and subjected to SDS–PAGE. The proteins were
transferred to Problott PVDF membrane (Applied Biosystems) when
Coomassie Brilliant Blue staining was required or to nitrocellulose
membranes for Western blotting.
2.6. Edman degradation
The in vitro cleavage assay was performed as described above but
the reaction components were multiplied by three in order to obtain
enough protein for sequencing. Once transfer was done onto Problott
PVDF membranes, the membrane was stained with Coomassie Bril-
liant Blue until the bands were visible, then destained with 50% meth-
anol and left to dry at room temperature. Edman sequencing was
performed by the Protein Sequencing and Peptide Synthesis Facility
at the Medical University of South Carolina and by the Microchemical
and Proteomics Facility at Emory University.
2.7. Sphingosine kinase assay
The assay was performed as described in [22] with slight modiﬁca-
tions. Brieﬂy, the cells were collected by centrifugation at 3000 · g
for 5 min. They were then resuspended in lysis buﬀer (20 mM Tris–
Cl pH 7.4, 1 mM EDTA, 0.5 mM Deoxypyridoxine, 15 mM NaF,1 mM b-mercaptoethanol, 1 mM sodium orthovanadate, 40 mM b-
glycerophosphate, 10% glycerol, 0.5% Triton X-100, 1.5 mM semicar-
bazide, supplemented with Complete Protease Inhibitor (Roche)). The
cell lysates were sonicated, centrifuged at 2500 · g for 15 min and pro-
tein concentration was determined on the supernatant. Equal amounts
of protein were then incubated with 50 lM sphingosine (delivered in
4 mg/ml fatty acid free BSA) and 1 mM ATP (5–10 lCi, dissolved in
200 mM MgCl2). The reaction was carried out for 30 min at 37 C.
It was stopped by the addition of 20 ll of 1 N HCl and 800 ll chloro-
form/methanol/HCl (100:200:1). After letting the samples sit at room
temperature for 10 min, 240 ll of chloroform and 240 ll of 2 M potas-
sium chloride were added, and the samples were centrifuged at
3000 · g for 5 min. The aqueous layer was aspirated, and 250 ll of
the organic layer were transferred to new glass tubes. The samples were
dried down in a speed vac and then resuspended in chloroform/meth-
anol/HCl (100:200:1). Lipids were resolved on silica TLC plates (What-
mann) using 1-butanol/methanol/acetic acid/water (80:20:10:20) as a
solvent system. Labeled S1P was visualized by autoradiography and
quantiﬁed by phosphoimager or by scraping and counting in a scintil-
lation counter.3. Results
3.1. Sequential in vitro cleavage of SK1 by cathepsin B
We previously showed that cathepsin B cleaves SK1 in vitro
to generate multiple cleavage fragments: one band at
31 kDa, one band at 23 kDa, two bands at 18 kDa,
and one band at 13 kDa [23]. In order to determine the
pattern in which these fragments were generated, a time
course with 5-fold lower concentration of cathepsin B was
performed (Fig. 1A). Incubation of SK1 with 1.3 munits/ll
(0.132 lM) of the protease showed that the ﬁrst major bands
to appear were the 31 kDa and the 23 kDa fragments. The
detection of these two bands suggests that there may be two
initial sites where cathepsin B cleaves SK1. To determine
the position of these sites, a Western blot was performed on
the in vitro cleavage assay products and the membrane was
probed with the SK1 polyclonal antibody directed against
the C-terminus of the protein (Fig. 1B). Using 0.3 U/ll of
cathepsin B, the ﬁrst prominent band to be detected by the
antibody had a molecular weight of 31 kDa. At 3.3 mun-
its/ ll of the protease, three other bands were clearly seen:
one band approximately 23 kDa, one around 21 kDa and
one at about 18 kDa. A time course analysis using recombi-
nant SK1 as a substrate showed that the 31 and the 23 kDa
bands appeared about the same time (Fig. 1C). The 18 kDa
band appeared later (Fig. 1C). These results suggest that
cathepsin B cleaves SK1 in a sequential manner with 2 initial
cleavage sites.3.2. Identiﬁcation of cathepsin B cleavage sites in SK1
To examine whether the cleavage bands on the Coomassie
stained membranes were the same as those on the Western
blot, we probed the Coomassie membrane from Fig. 1A with
the SK1 antibody. Fig. 2A shows that both Coomassie and
SK1 probed membranes generated the same pattern of bands:
one 31 kDa band and two close 23 kDa bands. The 18 kDa
bands on both membranes did not overlap exactly; the band
on the Coomassie stained gel was slightly lighter, suggesting
that this band does not contain the C-terminus of the SK1 pro-
tein [21]. Next, we elected to run the same experiment on a big-
ger polyacrylamide gel in order to obtain better separation and
resolution of the bands. As shown in Fig. 2B, the 31 kDa band
matched on the Coomassie and the probed membranes. A
Fig. 1. In vitro cleavage of SK1 by cathepsin B. (A) Recombinant SK1 was incubated with recombinant cathepsin B for various times in a cleavage
assay as described in Section 2. The products of the reaction were run on an SDS–PAGE, transferred to PVDF membrane and stained with
Coomassie Brilliant Blue. Several cleavage fragments were identiﬁed. (B) Dose response of recombinant cathepsin B incubated with 500 ng of
recombinant SK1. The products of the cleavage reaction were analyzed by Western blotting using an SK1 antibody. (C) Time course of recombinant
cathepsin B (1.3 munits/ll) incubated with 500 ng of recombinant SK1. The products of the cleavage reaction were analyzed by Western blotting
using an SK1 antibody.
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membrane. For this doublet, the lower band, which was more
intense, matched a band on the Coomassie stained membrane.
Two other SK1 bands, one less than 20 kDa and the other less
than 15 kDa, were also observed on the Western blot but did
not match any bands on the stained membrane. These results
indicate that the two initial cleavage fragments generated by
cathepsin B action on SK1 retain the C-terminal portion of
the protein. Moreover, since the 23 kDa and the 31 kDa bands
were both detected by the SK1 antibody, this suggests that the
23 kDa band is an N-terminal truncated derivative of the
31 kDa band.Next, the sites of cleavage for cathepsin B were determined.
To this end, the 31 kDa and the 23 kDa bands were excised
from the Problott PVDF membrane and subjected to Edman
degradation for the determination of the amino acid se-
quences. The 31 kDa band generated the sequence: XAX-
YEQV and the 23 kDa band the sequence LAALRTY.
Examining the SK1 amino acid sequences suggested that the
exact cleavage sites are at the H122-Y123 and the R199-
L200 peptide bonds (Fig. 2C). Calculating the molecular
weights for fragments extending from these cleavage sites to
the C-terminus of recombinant SK1 (which has a 6· His tag
at the C-terminus) generated bands with molecular weights
Fig. 2. Alignment of Coomassie membranes with Western blots. (A and B) Recombinant SK1 was incubated with recombinant cathepsin B and a
cleavage assay was performed as described in Section 2. The products of the reaction were run on an SDS–PAGE, transferred to PVDF membrane
and stained with Coomassie Brilliant Blue or probed for SK1 by Western blotting. The stained and the probed membranes were then aligned to
compare the sizes of the cleavage products detected by the two approaches. (C) SK1 sequence showing the cleavage sites identiﬁed by Edman
degradation; ﬁrst site after H122 (green) and second one after R199 (green). Expected molecular weights of fragments generated at H122 and R199
are also indicated. Weights in parentheses represent the mass of His-tagged recombinant SK1, which has six extra histidine residues at its C-terminus
(Bold). The P1 (green), P2 (purple), and P1 0 (purple) amino acids at the ﬁrst cleavage site are also indicated. Amino acids in blue are the residues
obtained by Edman sequencing; red amino acids were not detected by Edman sequencing.
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the sizes obtained on the Western blotted membranes. From
here on, the 31 kDa and the 23 kDa bands are renamed as
30 kDa and 21 kDa bands, respectively.
3.3. Mutation of the P1, P2, or P1 0 amino acids at the ﬁrst
cleavage site reduces cleavage by cathepsin B at that site
It has been previously proposed that the three sites P1, P2,
and P1 0 are the major amino acids determining cleavage spec-
iﬁcity by cathepsin B [24]. The P1 site is the amino acid after
which the protease cleaves, the P2 site is the amino acid up-
stream of P1, and the P1 0 is the amino acid downstream of
P1 (Fig. 2C). Because the 30 kDa band was the most promi-
nent cleavage fragment and the ﬁrst to appear, we generated
several SK1 point mutants at these three amino acids in the
presumed ﬁrst cleavage site and examined their sensitivities
to cleavage by the protease. Incubation of cell lysates transfec-
ted with wildtype or point mutants of SK1 with recombinant
cathepsin B showed that all were susceptible to cleavage(Fig. 3A) to degrees ranging from 30% in the H122A mutant
to 62% in the N121E mutant (Fig. 3B). Diﬀerences were also
observed in the ratio of the 30 kDa band to full length SK1,
which represents the eﬃciency of cleavage at the P1 amino acid
of the ﬁrst cleavage site. The cleavage eﬃciency of the wildtype
was set at 100% and all mutants were compared to it (Fig. 3C).
Interestingly, in all the mutants tested, the cleavage at the P1
site was lower than the wildtype. Mutations of the P1 histidine
to an alanine or a glutamate both appeared to be the most
eﬀective in reducing cleavage (up to 25%), followed by the
P2 and the P1 0 mutants, where reduction was by 18%
(Fig. 3C). These data suggest that the P1 histidine, followed
by the P1 0 tyrosine and the P2 asparagine are important deter-
minants of SK1 cleavage by cathepsin B at the P1 position.
3.4. Mutation of the P1, P2, or P1 0 amino acids at the ﬁrst
cleavage site reduces SK1 activity
Next, it was important to determine whether the mutations
in SK1 aﬀected the activity of the enzyme. To this end, the var-
Fig. 3. In vitro cleavage of SK1 mutants by cathepsin B. (A) Cleavage assay was performed by incubating recombinant cathepsin B with lysates from
MCF-7 cells overexpressing wildtype or mutant SK1. Products were analyzed by Western blotting for SK1. (B) Densitometric quantiﬁcation of the
percentage cleavage of wildtype or mutant SK1 by cathepsin B. (C) Densitometric quantiﬁcation of cleavage at the P1 amino acid residue of the ﬁrst
cleavage site of SK1 or its mutants. Comparisons were made to wildtype, which was set at 100%.
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were checked by an in vitro SK assay. Each activity was nor-
malized to its protein expression to control for variations in
expression. As shown in Fig. 4, all the mutants had lower
activity than the wildtype. In particular, the glutamate muta-
tions signiﬁcantly inhibited the enzyme activity by 80%, sug-
gesting that the introduction of a negative charge in this
























Fig. 4. SK assay on SK1 mutants. SK assay was performed on cell
lysates of MCF-7 cells transfected with wildtype or mutant SK1
proteins. Activity was normalized to SK1 protein expression (Fig. 3)
and reported as a percentage relative to wildtype activity, which was
set at 100%.tions also reduced the SK1 activity by 40% (Y123A) and
60% (H122A). Therefore, despite the ability to reduce cleavage
at the P1 site, none of these mutants had an activity that was
comparable to wildtype. From these results, it was not possible
to determine whether the decrease in cleavage at the P1 site
was due to general misfolding of the protein (which also re-
duced activity) or due to the mutation itself.3.5. An SK1 P1 tyrosine mutant is strongly resistant to cleavage
by cathepsin B at the ﬁrst cleavage site
It became important to identify a mutant that can reduce
cleavage at the ﬁrst cleavage site without compromising SK1
activity. To address this, we aligned SK1 proteins from diﬀer-
ent species and compared their P1, P2, and P1 0 amino acids.
The human, mouse and rat SK1s all have identical residues
at the P1 0 and the P2 positions (Fig. 5). The P1 residue, how-
ever, was diﬀerent in the rat SK1 where the histidine was re-
placed by a tyrosine (Fig. 5). Therefore, we reasoned that a
mutation of the P1-histidine to a tyrosine would unlikely inhi-
bit activity of SK1, yet might change its cleavage susceptibility.
Indeed, when SK1 activity in H122Y transfected cells was
compared to wildtype, no detectable diﬀerences were observed,
indicating that this mutant is fully functional (data not shown).
The susceptibility of H122Y to cleavage by cathepsin B was
then tested. The mutant showed no rescue from overall
cleavage of the full length enzyme (Fig. 6A and B). However,
Fig. 5. ClustalW alignment of a region of human, mouse, and rat SK1 proteins. The P1, P2, and P1 0 amino acid residues at the ﬁrst cleavage site
from all three species are indicated.
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ciency of cleavage at the ﬁrst cleavage site) was compared in
the H122Y and the wildtype sample, a 70% reduction in cleav-
age eﬃciency was observed (Fig. 6C). Interestingly, cleavage at
R199 was not reduced (possibly enhanced) (Fig. 6A). These re-
sults suggest that the decrease in the cleavage eﬃcacy of SK1
by cathepsin B at the ﬁrst cleavage site is a direct consequence
of the mutation rather than a change in enzyme folding (since
activity was unchanged). The data also suggest that the cleav-
age at ﬁrst site may not be necessary for cleavage at other sites
such as R199, since reduction of cleavage at the ﬁrst site nei-WT 67.5 32.5
H122Y 70.9 29.1





Fig. 6. SK1 (H122Y) activity and cleavage. (A) Cleavage assay was perform
overexpressing wildtype or mutant SK1. Products were analyzed by Western
cleavage of wildtype or H122Y SK1 by cathepsin B. (C) Densitometric quan
wildtype or H122Y SK1. Comparisons were made to wildtype, which was sther aﬀected the decrease in full length SK1 after cathepsin B
nor the generation of the 21 kDa cleavage fragments. Interest-
ingly, the 18 kDa fragment, however, was also signiﬁcantly re-
duced in the H122Y mutant, suggesting that this fragment may
be a cleavage product of the 30 kDa fragment.4. Discussion
In this study, we examined the mechanism of SK1 regulation
by cathepsin B in vitro. The cysteine protease cleaved SK1 atWT 100.0
H122Y 29.5







ed by incubating recombinant cathepsin B with lysates from Hela cells
blotting for SK1. (B) Densitometric quantiﬁcation of the percentage
tiﬁcation of cleavage at the P1 amino acid of the ﬁrst cleavage site of
et at 100%.
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199. Cathepsin B is a cysteine protease that acts as an exopep-
tidase at pH < 5.5 and as an endopeptidase at pH > 5.5 [3]. Its
cleavage speciﬁcity prefers, but is not restricted to, basic amino
acids at the P1 position and hydrophobic or arginine residues
at the P2 position [24]. The assays in this study were performed
at pH  6.0, supporting the endopeptidase activity of cathep-
sin B. The P1 residues identiﬁed at the two cleavage sites
(H122 and R199) are basic amino acids, consistent with the
preference of the enzyme as well.
An H122Y SK1 mutant showed signiﬁcant reduction of
cleavage at the ﬁrst site but did not aﬀect cleavage at the
R199 site or total cleavage of full length SK1. These results
lead to several conclusions. First, cleavage at H122 is not re-
quired for cleavage at R199, and cleavages at the two sites
are apparently independent of each other. Second, cathepsin
B cleaves SK1 very eﬃciently, such that mutation at one of
the cleavage sites (H122) does not rescue cleavage of the full
length enzyme. Therefore, it may be important to mutate more
than one cathepsin B cleavage site to obtain an SK1 resistant
to cleavage, or to identify the binding site for cathepsin B in
SK1 to inhibit the eﬀect of the protease on the enzyme. More-
over, cleavage sites for cathepsin B have been identiﬁed in Bid
at positions where the protein is ﬂexible [15,16]; hence it is pos-
sible to speculate that H122 and R199 in SK1 occupy regions
of the protein with fairly high mobilities, which allow them to
insert into the active site of cathepsin B, and point mutations,
although reduce the eﬃciency of binding, may not completely
abolish cleavage because of ﬂexibility of these regions.
Although we have sequenced two sites of cleavage by Edman
degradation, Coomassie stained gels and Western blots in
Fig. 2 showed that there were two cleavage bands with
molecular weights close to 20 kDa. While the lower band cor-
responded to cleavage at R199 and generated a band of 20–
21 kDa, another possible site which explains the upper band
is R186-L187 (Fig. 2C), since this site consists of arginines at
the P1 and the P2 sites, a preferred pattern for cleavage by
cathepsin B [24]. Cleavage at R186-L187 would generate a
fragment whose molecular weight is 22–23 kDa, in agreement
with the size observed on the membranes. However, this cleav-
age fragment appears to be in the same range as that of the ma-
ture form of the cathepsin B enzyme, suggesting that resolving
the two bands may be diﬃcult. Also, we have no evidence
whether cleavage at R186 (if it occurs) happens before, after,
or at the same time as that of R199. From Fig. 2C, however,
it appears that the two fragments are generated at the same
time or within a very short time frame from each other.
While the stringency for cleavage sites is lower for cathepsin
B than caspases and calpains, which engage in limited proteol-
ysis and have more deﬁned cleavage sites, cathepsin B does not
cleave randomly, and not all proteins are susceptible to cleav-
age by the protease. Vancompernolle et al. have shown that
cathepsin B can cleave caspases in vitro, yet the eﬃciency of
cleavage is not identical for all caspases. Proﬁcient cleavage
was observed for procaspases 1 and 11, whereas procaspases
2, 3, 6, 7, and 14 were weaker substrates, and procaspase 12
was not a substrate at all [25]. Hence, the ability of cathepsin
B to cleave SK1 places SK1 among a large, but still restricted,
library of substrates.
The cleavage of SK1 by cathepsin B is very likely to destroy
the enzyme activity of SK1 because the H122 cleavage site lies
between the proposed ATP binding site of the protease [26]and a residue that appears to be required for sphingosine bind-
ing [27]. Moreover, an SK1 mutant lacking amino acids 344–
384 has been shown to have reduced binding to calmodulin,
suggesting that such a deletion signiﬁcantly aﬀects the folding
of the protein and potentially its activity [26]. Therefore, cleav-
age at R199, which generates a larger deletion of SK1, is also
likely to misfold the protein and to aﬀect its activity as well.
Previously, we have shown that SK1, lysosomes, and cathep-
sin B signiﬁcantly colocalize in MCF-7 cells [23]. Under basal
conditions, SK1 and cathepsin B may be on diﬀerent faces of
the lysosome: cathepsin B on the luminal side and SK1 on
the cytosolic side, suggesting that the active site of the protease
does not ‘‘see’’ SK1. Under stimuli where lysosomes are dis-
rupted, cathepsin B is released into the cytosol, where the
pH is less acidic, inducing a shift in the speciﬁcity of the en-
zyme from an exopeptidase to an endopeptidase, thus enabling
it to ‘‘see’’ SK1 and eﬃciently cleave it at multiple sites, result-
ing in loss of the protein and a subsequent decrease in the SK1
activity.
In conclusion, this work has shown SK1 to be a cleavage
substrate for cathepsin B and has identiﬁed protease sensitive
sites in the enzyme. As such, SK1 is the ﬁrst sphingolipid
metabolizing enzyme shown to be directly cleaved by a prote-
ase in general, and a cysteine protease in particular.
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